StockData
Moderna, Inc. logo

Moderna, Inc. (MRNA) company profile

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$206.80−8.47 (-3.93%)

Close on Nov 17, 2026Market cap $82.56BP/E –Yield –

About Moderna

Biological Products, (No Diagnostic Substances), SIC 2836

Moderna is a biotechnology company focused on discovering, developing, and manufacturing medicines and vaccines powered by messenger RNA technology. Its commercial product lineup features respiratory immunizations, including Spikevax and mNEXSPIKE for COVID-19, as well as mRESVIA targeting respiratory syncytial virus. The firm organizes its pipeline across infectious diseases, oncology therapeutics, and rare disease treatments, actively evaluating candidates in late-stage clinical trials. Its products serve global populations spanning infants, high-risk individuals, and older adults, reaching patients through retail distribution, clinical healthcare settings, and government collaborations.

The enterprise operates a global manufacturing network with corporate and production facilities across the United States, the United Kingdom, Canada, and Australia, including a dedicated clinical batch supply center in Marlborough, Massachusetts. While corporate headquarters are not explicitly identified in the provided text, Moderna supplies and authorizes its medicines across more than forty international countries throughout North America, Europe, and the Asia-Pacific region.

Summary of the business section of Moderna's latest annual report, written by StockData.

Company profile

Company

Legal name
Moderna, Inc.
Founded
2010
Headquarters
Cambridge, MA
Address
325 Binney Street 02142
Phone
(617) 714-6500
Employees
4,700, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Boston, Massachusetts

Stock & identifiers

Ticker
MRNA
Exchange
Nasdaq
IPO date
Dec 7, 2018
Shares outstanding
399M, Jul 24, 2026
Public float
$9.90B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1682852
CUSIP
60770K107
ISIN
US60770K1079
FIGI
BBG003PHHZT1
Share class FIGI
BBG003PHHZV8
LEI
549300EI6OKH5K5Q2G38
EIN
81-3467528

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Stephane BancelChief Executive Officer, Director13,005,140
Juan AndresChief Operating Officer125,000
Stephen HogePresident1,792,614
James M. MockChief Financial Officer60,125
Shannon Thyme KlingerChief Legal Officer87,044
Soria Ester BanqueChief Commercial Officer–
Michael R. McDonnellDirector–
Noubar AfeyanDirector6,856,164
Abbas HussainDirector12,066
David M. RubensteinDirector9,643
Elizabeth E. TallettDirector4,761
Elizabeth G. NabelDirector19,317
Francois NaderDirector32,781
Sandra HorningDirector18,585
Paul SaganDirector494,133

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$19.93M$15.80M$9.77M$28$120
FY2024$19.88M$5.78M$14.59M$40$91
FY2023$17.07M-$155.55M$5.10M$95$92
FY2022$19.36M-$306.22M$5.82M$172$89
FY2021$18.16M$793.04M$8.26M$243$99
FY2020$12.86M$469.97M$5.29M$534$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Stéphane Bancel
Chief Executive Officer
$1.68M$6.90M$6.90M$4.30M$157.24K$19.93M+0%
James Mock
Chief Financial Officer
$852.19K$2.45M$1.23M$1.31M$15.75K$5.86M-66%
Stephen Hoge
President
$1.26M$9.20M$4.60M$2.98M$15.75K$18.05M+97%
Shannon Thyme Klinger
Chief Legal Officer and Corporate Secretary
$852.19K$2.15M$1.07M$1.31M$15.75K$5.40M-69%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Dec 7, 2018
Offer price
$23.00
Securities offered
26,275,993
Gross proceeds
$604.35M
Exchange
Nasdaq
First trading day
Dec 7, 2018
First-day close
$18.60-19.1%
Lock-up ends (est.)
Jun 5, 2019

“The initial public offering price of our common stock is $23.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“We had approximately 4,700 full-time employees in 18 countries as of December 31, 2025 .”

Corporate history

Events identified from SEC filings

DateEventDetails
Dec 7, 2018IPOInitial public offering priced (424B4 prospectus)
Dec 4, 2018ListingRegistration of securities on an exchange (Form 8-A)
Aug 24, 2016Name changeName changed from Moderna Therapeutics, Inc. to Moderna, Inc.

See a number that looks wrong?